LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cystic Pancreatic Lesion Bacteria Are Precursors to Pancreatic Cancer

By LabMedica International staff writers
Posted on 08 Dec 2021
Print article
Image: The BACT/ALERT 3D instrument is a state-of-the-art, automated microbial detection system (Photo courtesy of bio-Merieux)
Image: The BACT/ALERT 3D instrument is a state-of-the-art, automated microbial detection system (Photo courtesy of bio-Merieux)
Pancreatic cancer (PC) is one of the most aggressive and lethal types of cancer. The 5-year survival rate at the time of diagnosis is about 10%, as approximately 80%–85% of patients present either unresectable or metastatic disease. PC accounts for roughly 459,000 new cases and 432,000 deaths.

Cystic lesions, including intraductal papillary mucinous neoplasms (IPMNs), of the pancreas are common. Because they are known as precursors to pancreatic cancer, many patients need regular, lifelong check-ups, and a few can also require surgery. It would be valuable for the individual and for the healthcare to know more about the carcinogenic risk factors.

Medical Scientists at the Karolinska Institutet (Stockholm, Sweden) investigated the possibility to cultivate pancreatic microbiome from pancreatic cystic lesions associated with invasive cancer. Between February 2018 and November 2019, patients undergoing pancreatic surgery due to pancreatic cystic neoplasms (PCN) with cancer suspicion confirmed by radiological and clinical examinations participated in this study. Surgically removed pancreata were sampled for cyst fluid immediately upon resection in strict sterile conditions and cultured in aerobic and anaerobic blood culture bottles (BacT/ALERT 3D, bio-Merieux, Marcy l’Étoile, France). The culture-positive samples were streaked repetitively to obtain pure monocultures for a subsequent strain identification by MALDI-TOF MS profiling (MALDI-TOF MS Biotyper System (Bruker Daltonics, Bremen, Germany).

The investigators reported that 29 cases (24%) exhibited bacterial growth. Pancreas pathology revealed that all seven culture-positive cases had IPMN, of which five were in the high-grade dysplasia (HGD) stage or associated with invasive cancer (5/7; 71.4%). The culture-negative cases included only six malignant cases (6/21; 27.3%), the others were low-risk tumors such as IPMN-low grade dysplasia and serous cystic tumors (SCNs), and three cases also had signs of concomitant pancreatitis. MALDI-TOF MS profiling analysis shows Gammaproteobacteria and Bacilli dominate among individual bacteria isolates. Among cultivated bacteria, Gammaproteobacteria, particularly Klebsiella pneumoniae, but also Granulicatella adiacens and Enterococcus faecalis, demonstrate consistent pathogenic properties in pancreatic cell lines tested in ex vivo co-culture models.

Margaret Sällberg Chen, DDS, PhD, a Professor and senior author of the study said, “Some bacteria could cause double-stranded DNA breakage which is considered the first step of cellular lesion and cancer. We also found that antibiotics could prevent the damage to the DNA. Our findings not only confirm that bacteria play an important part in the development of cancer, they also illuminate new ways to attack the process.”

The authors concluded that their results showed an over-representation of Gammaproteobacteria and another class of bacterium called Bacilli. These bacteria reside normally in the digestive tract and have previously been shown to promote cancer drug resistance by interfering the effect of gemcitabine, a cytostatic drug used in pancreatic cancer treatment. The study showed that these bacteria were present in IPMNs and culturable in 24% of the cases. The study was published on November 24, 2021 in the journal Gut Microbes.


Related Links:
Karolinska Institutet
bio-Merieux
Bruker Daltonics


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.